Therapeutic Area
Rare Disease CDMOs
Compare CDMOs with rare disease manufacturing expertise for orphan drugs, enzyme replacement therapies, gene therapies, and ultra-small batch production. Filter by modality, scale, and regulatory experience.
89 companies listed
About Rare Disease Drug Manufacturing
Rare disease (orphan drug) manufacturing presents unique challenges. Patient populations are small -- often under 10,000 patients worldwide -- so batch sizes are correspondingly small. But the manufacturing complexity is often extreme: gene therapies, enzyme replacement therapies, substrate reduction therapies, and RNA therapeutics dominate the pipeline. The cost per dose can exceed $100,000, making manufacturing efficiency and batch success rates critically important.
Gene therapy is reshaping rare disease treatment. Over 30 approved gene therapies target rare diseases, with hundreds more in clinical development. Manufacturing AAV vectors for conditions like spinal muscular atrophy, hemophilia, and inherited retinal dystrophy requires specialized viral vector production facilities, scalable purification processes, and potency assays specific to each product. CDMOs with flexible, multi-product vector manufacturing capabilities are in high demand.
Flexibility beats scale for rare disease CDMOs. Unlike cardiovascular or diabetes drugs that need massive throughput, rare disease products need CDMOs that can efficiently handle 10-100 batch campaigns per year. Multi-product facilities with short changeover times, validated cleaning procedures for potent and biologic products, and regulatory experience with orphan drug designations (FDA, EMA) provide the most value to sponsors in this space.
Companies (89)
UPM Pharmaceuticals
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of semi-solid and oral solid dose products. Operating from a 475,000 sq ft cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 30+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
Small Molecule Drug ProductOral Solid DoseFormulation Development
PeptiStar Inc.
Japan
PeptiStar is a Japan-based CDMO specializing in the development and cGMP manufacture of peptide and oligonucleotide APIs. From its 10,500 m² R&D and manufacturing site in Settsu, Osaka, the company supports programs from milligram-scale research material through clinical and commercial production. PeptiStar works with complex peptide structures, including long-chain, cyclic, branched and constrained peptides, non-natural amino acids and peptide conjugates. Its route-flexible manufacturing platform includes conventional and microwave-assisted SPPS, STag-PS and SYNCSOL liquid-phase technologies. Integrated downstream capabilities include preparative and continuous chromatography, membrane concentration and lyophilization, with 300 L filter reactors, chromatography columns up to 450 mm and lyophilizers up to 500 L. Purification and subsequent processing are conducted in Class 100,000 controlled areas. PeptiStar also develops and manufactures oligonucleotide APIs and peptide–oligonucleotide conjugates. The company was recognised by Exelixis as its 2025 CDMO of the Year.
Peptide APIOligonucleotide APIAPI Manufacturing
Frequently Asked Questions
What makes rare disease manufacturing different from other therapeutic areas?+
Three factors distinguish rare disease manufacturing. First, batch sizes are small (often 100-10,000 doses per year), so CDMO economics must work at low volumes. Second, products are often highly complex -- gene therapies, enzyme replacements, and other biologics that require sophisticated manufacturing and analytics. Third, the regulatory pathway offers incentives (orphan drug designation, accelerated approval) but also unique challenges around clinical endpoints and post-market commitments.
How do orphan drug economics affect CDMO selection?+
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
